International Journal of Scientific Research in Science and Technology
Print ISSN: 2395-6011 | Online ISSN: 2395-602X (www.ijsrst.com)
doi : https://doi.org/10.32628/IJSRST

Effect of Bergamot Polyphenolic Fraction on level of HDL-C & LDL-C

Kanika[1], Prashant[2]
[1]Sat Kabir college of pharmacy, Village Ladrawan, Tehsil Bahadurgarh, District Jhajjar.
[2]Delhi, India

ARTICLEINFO

Article History:

Accepted: 05 May 2023
Published: 20 May 2023

Publication Issue
Volume 10, Issue 3
May-June-2023

Page Number
274-281

ABSTRACT

A well-established modifiable cardiovascular risk component is low density lipoprotein (LDL-C). Although statins can lessen LDL-c through 50–60%, less than 20% of patients with excessive risk of CVD acquire LDL targets. The purpose of this systematic review is to assess the impact of the nutraceutical, bergamot (Citrus bergamia), on lipid parameters in humans. Based on data, 75% of studies confirmed a significant lower in overall cholesterol, triglycerides and LDL-c. The lower in overall cholesterol varied from 12.3% to 31.3%, from 7.6% to 40.8% in LDL-c and from 11.5% to 39.5% in triglycerides. The incidence of metabolic syndrome (MS) represents an independent risk factor for developing cardiovascular disorder states in patients affected by type 2 diabetes mellitus. Moreover, both the size of LDL particles and liver disorder recognized as non- alcoholic steato-hepatitis (NASH) constitute essential biomarkers for the improvement of cardiometabolic risk in patients with MS. Recent evidence indicates that bergamot polyphenolic fraction (BPF) in patients with MS and NASH induces a significant decrease of fasting plasma glucose, serum LDL cholesterol and triglycerides along with an increase of HDL cholesterol. In addition, a significant reduction of both ultrasonographic, TC scans and metabolic biomarkers of NASH in addition to a significant reduction of small dense LDL particles have been determined after BPF treatment suggesting a useful impact of bergamot-extract in patients with MS and NASH. In this regards, emerging evidence indicates a capability protecting function of bergamot extracts, specially bergamot flavonoids, in the control of various features of MetS (metabolic syndrome), because of their pleiotropic anti-oxidative, anti-inflammatory and lipid- reducing results. The purpose of this review is to discuss the beneficial effects of bergamot polyphenols providing a brand-new therapeutic method in the treatment of cholesterol.

KEYWORDS - metabolic syndrome (MetS), LDL-C, triglycerides, bergamot Polyphenolic fraction, Cardiovascular

I. INTRODUCTION

Bergamot (Citrus bergamia) is a pandemic plant of the Calabrian area in Southern Italy with a completely unique profile of flavonoid and flavonoid glycosides found in its juice and albedo, along with neoeriocitrin, neohesperidin, naringin, melitidin and brutieridin. Bergamot differs from different Citrus fruits not most effective because of the composition of its flavonoids, however also because of their especially excessive content [1,2]. Among them naringin, present additionally in grapefruit, has already been suggested to be energetic in animal models of atherosclerosis [4], while neoeriocitrin and rutin have been shown to inhibit LDL oxidation [3]. Importantly, bergamot juice is high in neohesperidosides and naringenin, along with melitidine and brutieridine. These flavonoids possess a 3-hydroxy-3-methylglutaryl moiety with a structural similarity to the natural substrate of 5-hydroxy-3-methylglutaryl-coenzyme a reductase and exhibit statin-like proprieties [5].

Evidence has been accumulated demonstrating that MetS is a cluster of numerous cardiometabolic risk factors, which includes hyperglycemia or glucose intolerance, excessive levels of triglycerides (TG) and low - density lipoprotein cholesterol (LDL-C) and low stages of excessive -density lipoprotein cholesterol (HDL-C), hypertension and diabetic. Bergamot polyphenolic fraction (BPF) is capable of produce lipid impact observed by development of endothelial feature and reduction of cardiometabolic chance. In particular, BPF supplementation has been shown to lessen serum cholesterol, LDL and triglycerides, main to tremendous improvement of general parameters of lipid profile. Indeed, a significant reduction of cholesterol absorption has been established to occur following supplementation with BPF, an impact which appears to be associated with the inhibition of pancreatic cholesterol ester hydrolase (pCEH); an enzyme which contributes in the cholesterol absorption[6,7].

II. BIOSYNTHESIS OF CHOLESTEROL

It acting directly on the rate limiting enzyme hydroxy-methyl-glutaryl CoA reductase (HMGCoA reductase) [5]. In particular, BPF has been shown to include huge quantities of glycosylated polyphenols (mainly bruteridine and melitidine), which have been shown to own statin-like property, thereby inhibiting HMGCoA reductase [6].

Finally, we've confirmed that BPF modulates AMP (adenosine monophosphate)-activated protein kinase (AMPK) which performs a key function in the regulation of the metabolic pathways concerned in ATP production. On the alternative hand, AMPK performs a important function in the integrated modulation of both lipidic and glycidic metabolism withinside the liver, while dysregulation of AMPK has been related to fats accumulation and liver disorder in subjects with hyperlipemia [8]. Thus BPF, because of this impact in modulating AMPK, contributes to a higher lipemic profile. In particular, the mechanism main to BPF-associated conversion of cholesterol to cholesteryl esters and the following lipoprotein assembly represents an impact primarily because of the activity of the Lipid Transfer Protein system. On the alternative hand, the action of bergamot polyphenols on folding useful HDLs and improving lipid change amongst distinctive lipoproteins, concerning the impact of BPF on HDL levels in hyperlipemic patients, needs to be further explored [9,11].

Effects of BPF on liver steatosis and LDL cholesterol

The role of BPF in reducing LDL Cholesterol, triglycerides and glucose in patients suffering from MS is observed by reduction of LDL-C and elevation of HDL-C. This useful impact in the lipemic profile of patients suffering MS is also characterised through distinguished rearrangement of lipoprotein particle profile observed following 120day BPF treatment. Indeed, BPF decreased small size, atherogenic LDL substances. This impact, mixed with reduction of

inflammatory biomarkers, indicates that BPF results in an attenuation of atherogenic risk in patients with MS [12].

The mixed impact of BPF in lowering both cholesterol and triglycerides may also well give an explanation for lipoprotein re-arrangement because of prolonged BPF treatment. Indeed, an elevated clearance of TG-high lipoprotein substances makes these substances became better substrates for lipoprotein lipase. This would be expected to result in reduced levels of huge and medium-sized VLDL and possibly even intermediate density lipoprotein (IDL), which includes more or less same quantities of TG and cholesterol [13].

The extended cascade of VLDL to IDL to LDL could result in extended numbers of huge LDL substances and provide surface ingredients for the formation of large HDL. The formation of small LDL is in particular because of cholesteryl ester transfer protein-mediated change of VLDL-TG for LDL cholesterol ester and the following hydrolysis of LDL-TG. The lower in large and medium VLDL diminishes the cholesteryl ester transfer protein-mediated change, lowering the formation and wide variety of small LDL substances.

Recently, it's been shown that MS is related to non-alcoholic fatty liver disease (NAFLD) [14]. The improvement of hepatocyte characteristic observed in patients with MS and related NAFLD after taking BPF may also contribute in the amelioration in lipoprotein profile thereby attenuating cardiometabolic risk [14].

Some studies have established that insulin resistance nearly universally induces NAFLD [13,14]. It is understood that this situation may precede the improvement of cardiovascular disease [15]. To confirm the connection between NAFLD and atherosclerosis, carotid atherosclerosis has currently been detected in patients with NAFLD [16]. Pathogenetic mechanisms responsible for that consist of an elevated lipolysis and increased transport of free fatty acids to the liver [16]. The improvement of steato test and hepatorenal index in patients with MS and NAFLD following BPF treatment offers a quantitative estimation of steatosis and results in the conclusion that BPF improves each liver characteristic and symptoms and symptoms of persistent liver irritation, as showed by reduction of TNF and CRP [17].

Mild to moderate elevations of serum aminotransferases (ALT and AST) observed in BPF-treated patients subjects at baseline represents the maximum common abnormality observed in patients with NAFLD. Their serum ranges have been significantly decreased after BPF, thereby confirming statistics received with steato test and hepatorenal index.

The mechanism of the hepato-protecting effect of BPF still stays to be elucidated. However, evidence suggests that BPF acts as a cytoprotective agent in liver of rats administered an excessive cholesterol diet [18]. The probably clarification is associated with BPF BPF activities in oxidative inflammation and modifications in hepatocyte membrane permeability possibly through stabilization of the hepatocyte membrane structure, thereby preventing pollutants from entering the cells. In addition, different oblique cytoprotectìve impact may be due to the modulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) ranges, probably through binding bile acids and increasing the turnover rate of blood and liver cholesterol [18], and to the enhancement in the excretion of fecal sterols. As referred to above, the hypolipidemic reaction discovered in patients undergoing BPF treatment can be associated with the modulatory properties of naringin and neohesperidin, through inhibition of hepatic TG accumulation. Thus, BPF polyphenolic components, through unique mechanisms lessen liver characteristic accumulation of fats thereby generating an usual improvement of liver.

Lipid-lowering and Anti-diabetic Effects of BPF

In the context of MetS, several beneficial results of BPF have been detected in scientific trials. In this regard, BPF has proven essential properties while administered in patients suffering from isolated hypercholesterolemia, patients with hyperlipidemia (hypercholesterolemia and hypertriglyceridemia) and patients with combined hyperlipidemia associated with hyperglycemia [18]. All patients obtained an oral dose of BPF (500 mg or 1000 mg) for 30 consecutive days. At the end of the treatment period, all patients have shown a strong reduction in TG, TC, LDL-C, blood glucose stages and a significant increase in HDL-C, that is dose-dependent. Interestingly, decreased excretion stage of urinary mevalonate become stated suggesting an immediate inhibitory motion of BPF on 5-hydroxy-3-methylglutaryl-coenzyme a reductase activity. The latter evidence might be because of the structural similarity to 5-hydroxy-3-methylglutaryl-coenzyme a reductase substrate shown through bruteridine and melitidine, which are 3-hydroxy-3-methylglutaryl derivatives of hesperetin and naringenin, respectively. Furthermore, BPF improves the impaired endothelium-mediated vasodilation in all treated patients. The reduction of all cholesterol parameters, because of BPF treatment, become additionally proven in a sub-organization of patients with a relevant intolerance to statins [13]. Gliozzi and associates well proven that the co-treatment with rosuvastatin (10 mg/daily/p.o.) and BPF (1000 mg/daily/p.o.) for 30 days appreciably complements the impact of rosuvastatin alone on serum lipemic profile of patients with hyperlipemia [14]. This impact is related to significant reduction of MDA, lectin-type oxidized LDL receptor 1 (LOX-1) and p-PKB levels, suggesting a multi-action capability for BPF in patients on statin therapy [14]. In a work published in 2014, the identical studies institution studied the impact of BPF on LDL small dense substances and NAFLD, any other essential biomarker for the improvement of cardiometabolic risk, in patients with MetS [15]. Interestingly, a significant reduction in serum TC, LDL-C and TG.

Patients treated with BPF (500 mg, two times a day, p.o.) for 120 consecutive days. This impact is related to a significant reduction of serum glucose, transaminases, gamma-glutamyl-transferase and inflammatory biomarkers which includes TNF-α and C-reactive protein (CRP) [19]. Moreover, BPF is able of a enormous re-association of lipoprotein substances. It reduces LDL small-length atherogenic substances and complements large-length anti-atherogenic HDL substances [19].

In a MetS patients with accelerated atherogenic index of plasma (AIP) and mild hyperglycemia, the efficacy of a brand-new bergamot juice-derived method was reported [16]. Bergamot polyphenolic extract complex (BPE-C) is enriched with flavonoids, pectins and diet C. In patients treated with 500 or 1000 mg of BPF for 90 consecutive days, the clean development of dyslipidemia become confirmed, as previously reported [16]. In addition, a effective reduction of AIP and the amelioration of insulin sensitivity followed through weight reduction had been observed. This proof is related to a significant reduction of circulating leptin and ghrelin and upregulation of adiponectin [16]. Recently, BPF novel phytosomal system (BPF phyto) become evolved to attain a higher absorption and tissue distribution of BPF in patients suffering from T2DM and combined hyperlipemia [17].

After randomization, patients receive BPF (500 mg/p.o.) or BPF Phyto (500 mg/p.o.) two times a day for 30 consecutive days. The information received properly showed previous effects showing the beneficial results of BPF in enhancing lipid profile of patients The lipid-decreasing and anticholesterolemic results of BPF have been previously found in rat fed with hypercholesterolemic diet [20]. The information have shown that the administration of BPF for 30 days produces a significant reduction in TG, TC and LDL-C observed by mild elevation of HDL-C.

Moreover, in the BPF-treated group, a higher epato-biliary turnover and cholesterol intake was observed as recommended by extended levels of overall bile acids and impartial sterols in fecal samples [19]. The beneficial properties of BPF in counteracting the detrimental functions of NAFLD have been studied in cafeteria (CAF) diet-triggered rat model of MetS [18]. The effects showed that BPF had a function in decreasing serum TG, blood glucose and obesity. Moreover, BPF counteracts hepatic steatosis strongly lowering the quantity of lipid droplets in rat hepatocytes. BPF additionally prevents the pathogenic lipid accumulation through stimulating the autophagic system in the liver. Specifically, the phytocomplex exerts a powerful induction of lipophagy, as documented through the better ranges of LC3II located withinside the lipid droplet (LD) subcellular fractions of BPF-reveal livers [18].



Graph 1: Blood glucose, lipid and tryglyceride levels obtained at baseline and after treatment with BPF (500 mg once a day & 1000 mg once a day for 120 consecutive days) in patients suffering from MS, diabetic patients with MS, Anti-oxidant & anti-inflammatory and NAFLD.

III. DISCUSSION

This is the first systematic review aiming to explore the impact of bergamot in lipid profile in humans. We discovered 13 studies of which: 10 showed significant lower of overall cholesterol, triglycerides and LDL cholesterol; 2 most effective showed significant lower in LDL cholesterol; and 1 did not discover significant extrade in any lipid variable. Ten reported HDL cholesterol increase after intervention with bergamot in any form, while 3 studies defined moderate but significant decreases in HDL cholesterol concentration. A dose-established effect may be deduced from the studies but it should be confirmed with large trials. However, it is important to factor out that studies had quite heterogenous designs and scientific exceptional of the studies was quite limited. The first difficulty is important to attain conclusions because bergamot become supplied in distinct forms: (a) isolated phytosterols of bergamot; (b) dry extract of complete bergamot juice; and (c) as a part of a complicated nutraceutical consisting of different materials like phytosterols. Thus, a bergamot has a extensive impact on lipid profile in humans, which would be the most suitable dose, and the mechanism liable for this benefit. Statins are the primary therapeutic method in MetS (Metabolic syndrome) control because of their solidly proven cholesterol lowering and cardiovascular protecting effect (Stone et al. 2014; Baigent et al. 2005). However, a few subjects display statin-intolerance specially at excessive doses (Rosenson et al.2017; Serban et al. 2017). Inadequate lipid-reducing therapy and nonadherence to statin remedy are the primary reasons of failing to obtain LDL cholesterol targets (Guglielmi et al.2017). Nutraceuticals can assist to obtain lipid therapeutic goals and decrease cardiovascular residual risk. It established that nutraceuticals attain an LDL cholesterol reduction from A dose-response effect could be deducted from the evaluate we've analyzed. Overall, higher decreases in overall cholesterol, LDL cholesterol, and triglycerides were determined with higher bergamot doses. Although we found a linear affiliation among bergamot dose and lipid profile improvement, there is a excessive variant in the lipid profile reduction inside these studies. In this way, Cai et al. (2017) suggested a lower in LDL cholesterol of 7.63% when taking 500 mg/day dose of bergamot, while the identical dose brought about a lower of 24.1% in the trial performed through Mollace et al. (2011) On the alternative hand, the examine performed through Toth et al. (2015)

protected a low dose of 150 mg/day of flavonoids coming from bergamot and that they discovered a 18.2% crease in LDL cholesterol. Based on the alternative trials, a decrease impact could were anticipated if a linear dose response could had existed. It is essential to be aware that contributors traits are quite unique amongst trials and, One of the principle observations received of this systematic evaluate is that including bergamot to low-doses of statins brought about a comparable lipid profile development than will be reached with better doses, suggesting a synergic impact among statins and bergamot. while including bergamot to simvastatin 20 mg with appreciate to people who acquired simvastatin 40 mg. High-hazard or very-excessive-hazard patients with partial statin intolerance (who can tolerate a dose of statin this is much less than required primarily based totally on their cardiovascular hazard) will be benefited by this therapeutic option (Banach et al. 2018).

IV.CONCLUSION

The nutraceutical technique for the improvement of lipid profilr may also constitute a promising method in preventing cardiometabolic risk. In particular, polyphenols utilized in medical exercise had diabetes mellitus, MS and their complications and to favourably modulate some of biochemical and medical endpoints [25]. Bergamot-deriving polyphenolic fraction has been proven to own useful results in patients suffering MS as confirmed by a concomitant amelioration of lipemic and glycemic profile and by an improvement of the impaired endothelium-mediated vasodilation. In addition, in patients with MS and NAFLD, BPF significantly reduces liver steatosis. All those results are because of multi-action properties of bergamot derivatives which modulate key signalling proteins worried withinside the pathogenesis of MS and, on the alternative hand, at once counteract oxidative strain losing new mild at the capacity use of BPF for decreasing cardiometabolic hazard in sufferers with MS. The mechanism via which BPF improves lipemic profile through modulation of Lipid Transfer Protein System wishes to be in addition clarified. Possible synergistic impact will be explained due to the fact the mechanism of bergamot acts to unique levels: inhibiting the HMG-CoA reductase, the pancreatic cholesterol ester hydrolase and Acyl-CoA cholesterol acyltransferase, which could produce decrease cholesterol synthesis and better cholesterol fecal excretion. Promising findings give away from an opportunity healing choice in dyslipidemia control with bergamot supplementation, specially in patients with mild hypercholesterolemia, low cardiovascular risk or illiberal to standard pharmacological treatment. However, essential problems are still remained to be Overall, this is in favour of BPF dietary supplementation in hyperlipemic disease states to antagonize cardiometabolic risk.
been proven to goal the pathogenesis of

V. REFERENCES

[1]. Haffner, S.M., Lehto, S., Rönnemaa, T., Pyörälä, K. and Laakso, M. (1998) Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Non Diabetic Subjects with and without Prior Myocardial Infarction. New England Journal of Medicine, 339, 229-234. http://dx.doi.org/10.1056/NEJM199807233390404

[2]. Thalhammer, C., Balzuweit, B., Busjahn, A., Walter, C., Luft, F.C. and Haller, H. (1999) Endothelial Cell Dysfunction and Arterial Wall Hypertrophy Are Associated with Disturbed Carbohydrate Metabolism in Patients at Risk for Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 19, 1173-1179. http://dx.doi.org/10.1161/01.ATV.19.5.1173

[3]. Juutilainen, A., Lehto, S., Rönnemaa, T., Pyörälä, K. and Laakso, M. (2008) Similarity of the Impact of Type 1 and Type 2 Diabetes on Cardiovascular Mortality in Middle-Aged

Subjects.DiabetesCare,31,714-719. http://dx.doi.org/10.2337/dc07-2124

[4]. Hu, F.B., Stampfer, M.J., Haffner, S.M., Solomon, C.G., Willett, W.C. and Manson, J.E. (2002) Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes. DiabetesCare,25,1129-1134. http://dx.doi.org/10.2337/diacare.25.7.1129

[5]. Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.R. and Groop, L. (2001) Cardiovascular Morbidity and Mortality Associated with the Metabolic Syndrome. Diabetes Care, 24, 683-689. http://dx.doi.org/10.2337/diacare.24.4.683.

[6]. Sampson, U.K., Fazio, S. and Linton, M.F. (2012) Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges. Current Atherosclerosis Reports, 14, 1- 10. http://dx.doi.org/10.1007/s11883-011-0219-7

[7]. Berneis, K., Jeanneret, C., Muser, J., Felix, B. and Miserez, A.R. (2005) Low Density Lipoprotein Size and Subclasses Are Markers of Clinically Apparent and Non-Apparent Atherosclerosis in Type 2 Diabetes. Metabolism, 54, 227-234.

[8]. Krauss, R.M. (2004) Lipids and Lipoproteins in Patients with Type 2 Diabetes. Diabetes Care, 27, 1496-1504. http://dx.doi.org/10.2337/diacare.27.6.1496

[9]. Rizzo, M., Pernice, V., Frasheri, A., Di Lorenzo, G., Rini, G.B., Spinas, G.A. and Berneis, K. (2009) Small, Dense Low-Density Lipoproteins (LDL) Are Predictors of Cardio and Cerebro-Vascular Events in Subjects with the Metabolic Syndrome. Clinical Endocrinology (Oxf), 70, 870-875. http://dx.doi.org/10.1111/j.1365-2265.2008.03407.x

[10]. Austin, M.A., Breslow, J.L., Hennekens, C.H., Buring, J.E., Willett, W.C. and Krauss, R.M. (1988) Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction. JAMA, 260, 1917-1921. http://dx.doi.org/10.1001/jama.1988.03410130125037

[11]. Feingold, K.R., Grunfeld, C., Pang, M., Doerrler, W. and Krauss, R.M. (1992) LDL Subclass Phenotypes and Triglyceride Metabolism in Non-Insulin Dependent Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology, 12, 1496-1502. http://dx.doi.org/10.1161/01.ATV.12.12.1496

[12]. Krayenbuehl, P.A., Wiesli, P., Schmid, C., Lehmann, R., Spinas, G.A. and Berneis, K. (2008) Insulin Sensitivity in Type 2 Diabetes Is Closely Associated with LDL Particle Size. Swiss Medical Weekly, 138, 275-280.

[13]. Chait, A., Brazg, R.L., Tribble, D.L. and Krauss, R.M. (1993) Susceptibility of Small, Dense, Low-Density Lipoproteins to Oxidative Modification in Subjects with the Atherogenic Lipoprotein Phenotype, Pattern B. American Journal of Medicine, 94, 350-356. http://dx.doi.org/10.1016/0002-9343(93)90144-E

[14]. Younis, N., Charlton-Menys, V., Sharma, R., Soran, H. and Durrington, P.N. (2009) Glycation of LDL in Non-Diabetic People: Small Dense LDL Is Preferentially Glycated Both in Vivo and in Vitro. Atherosclerosis, 202, 162-168. http://dx.doi.org/10.1016/j.atherosclerosis.2008.04.036

[15]. American Diabetes Association. Position Statement (2012) American Diabetes Association Standards of Medical Care in Diabetes. Diabetes Care, 35, S11-S63.

[16]. Eknoyan, G., Hostetter, T., Bakris, G.L., Hebert, L., Levey, A.S., Parving, H.H., Steffes, M.W. and Toto, R. (2003) Proteinuria and Other Markers of Chronic Kidney Disease: A Position Statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). American Journal of Kidney Diseases, 42, 617-622.http://dx.doi.org/10.1016/S0272-6386(03)00826-6

[17].Ong, J.P., Pitts, A. and Younossi, Z.M. (2008) Increased Overall Mortality and Liver-Related Mortality in Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 49, 608-612. http://dx.doi.org/10.1016/j.jhep.2008.06.018

[18].Wang, Y., Li, Y.Y., Nie, Y.Q., Zhou, Y.J., Cao, C.Y. and Xu, L. (2013) Association between Metabolic Syndrome and the Development of Non-Alcoholic Fatty Liver Disease. Experimental and Therapeutic Medicine, 6, 77-84.

[19].Tarantino, G. (2007) Should Non-Alcoholic Fatty Liver Disease Be Regarded as a Hepatic Illness Only? World Journal of Gastroenterology, 13, 4669-4672.

[20].Hamaguchi, M., Kojima, T., Takeda, N., Nakagawa, T., Taniguchi, H., Fujii, K., Omatsu, T., Nakajima, T., Sarui, H., Shimazaki, M., Kato, T., Okuda, J. and Ida, K. (2005) The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease. Annals of Internal Medicine, 143, 722-728.

[21].Kim, H.M., Kim, D.J., Jung, I.H., Park, C. and Park, J. (2007) Prevalence of the Metabolic Syndrome among Korean Adults Using the New International Diabetes Federation Definition and the New Abdominal Obesity Criteria for the Korean People. Diabetes Research and Clinical Practice,77,99-106. http://dx.doi.org/10.1016/j.diabres.2006.10.009

[22].Seo, H.I., Cho, Y.K., Lee, W.Y., Rhee, E.J., Sung, K.C., Kim, B.S., Son, B.H., Shin, J.H., Joo, K.J., Hong, H.P., Chae, S.W. and Jin, W. (2012) Which Metabolic Syndrome Criteria Best Predict the Presence of Non-Alcoholic Fatty Liver Disease? Diabetes Research and Clinical Practice, 95,19-24. http://dx.doi.org/10.1016/j.diabres.2011.08.013

[23].Kotronen, A. and Yki-Järvinen, H. (2008) Fatty Liver: A Novel Component of the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 27-23. http://dx.doi.org/10.1161/ATVBAHA.107.147538

[24].Aguirre, L., Hijona, E., Macarulla, M.T., Gracia, A., Larrechi. I., Bujanda. L., Hijona, L. and Portillo, M.P. (2013) Several Statins Increase Body and Liver Fat Accumulation in a Model of Metabolic Syndrome. Journal of Physiology and Pharmacology, 64, 281-288.

[25]. Tsai, C.H., Li, T.C. and Lin, C.C. (2008) Metabolic Syndrome as a Risk Factor for Non-Alcoholic Fatty Liver Disease. Southern Medical Journal,101,900-905.